



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Transthyretin-IN-3

Cat. No.:	HY-161505
CAS No.:	3008535-20-1
Molecular Formula:	C ₁₇ H ₁₁ ClI ₂ O ₃
Molecular Weight:	552.53
Target:	Transthyretin (TTR)
Pathway:	Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Transthyretin-IN-3 (compound 6) is a designed benzofuran analogue. Transthyretin-IN-3 selectively binds to plasma transthyretin (TTR) to inhibit Amyloid aggregation (IC ₅₀ =5.0±0.2 μM). Transthyretin-IN-3 can bind to TTR's thyroxine binding site specifically by carrying chlorine substituents at specific locations in its structure. This binding can prevent TTR tetramers from dissociating into unstable monomers ^[1] .																					
In Vivo	<p>Transthyretin-IN-3 (0.1 mg/kg, iv; 0.1 mg/kg, po; 8 h) had an oral bioavailability (BA) of 66.8%, comparable to the current therapeutic drug Tafamidis (HY-14852) in SD rats^[1]. Pharmacokinetic Analysis in SD rats^[1]</p> <table border="1"> <thead> <tr> <th>Route</th> <th>Dose (mg/kg)</th> <th>C₀/max (ng/mL)</th> <th>CL_{tot} (mL/h/kg)</th> <th>V_{dss} (mL/kg)</th> <th>AUC₀₋₈ (ng·h/mL)</th> <th>BA (%)</th> </tr> </thead> <tbody> <tr> <td>i.v.</td> <td>0.1</td> <td>1718</td> <td>20.6</td> <td>112</td> <td>3726</td> <td>/</td> </tr> <tr> <td>p.o.</td> <td>0.1</td> <td>395</td> <td>/</td> <td>/</td> <td>2524</td> <td>67.7</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	Route	Dose (mg/kg)	C ₀ /max (ng/mL)	CL _{tot} (mL/h/kg)	V _{dss} (mL/kg)	AUC ₀₋₈ (ng·h/mL)	BA (%)	i.v.	0.1	1718	20.6	112	3726	/	p.o.	0.1	395	/	/	2524	67.7
Route	Dose (mg/kg)	C ₀ /max (ng/mL)	CL _{tot} (mL/h/kg)	V _{dss} (mL/kg)	AUC ₀₋₈ (ng·h/mL)	BA (%)																
i.v.	0.1	1718	20.6	112	3726	/																
p.o.	0.1	395	/	/	2524	67.7																

REFERENCES

[1]. Mizuguchi, Mineyuki, et al. "Development of Benziodarone Analogues with Enhanced Potency for Selective Binding to Transthyretin in Human Plasma." Journal of Medicinal Chemistry (2024).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA